Statement of Polish Respiratory Society and Polish Society
of Allergology on the treatment of pulmonary complications
in patients after SARS-CoV-2 infection
Wojciech J. Piotrowski
1
,
Adam Barczyk
2
,
Andrzej Chciałowski
3
,
Joanna Chorostowska-Wynimko
4
,
Małgorzata Czajkowska-Malinowska
5
,
Aleksander Kania
6
,
Maciej Kupczyk
7
,
Krzysztof Sładek
6
,
Marek Kulus
8
,
Paweł Śliwiński
9
Klinika Pneumonologii, I Katedra Chorób Wewnętrznych, Uniwersytet Medyczny, Łódź, Polska
Katedra i Klinika Pneumonologii, Śląski Uniwersytet Medyczny, Katowice, Polska
Klinika Chorób Infekcyjnych i Alergologii, Wojskowy Instytut Medyczny, Warszawa, Polska
Zakład Genetyki i Immunologii Klinicznej, Instytut Gruźlicy i Chorób Płuc, Warszawa, Polska
Kujawsko-Pomorskie Centrum Pulmonologii, Bydgoszcz, Polska
Klinika Pulmonologii, II Katedra Chorób Wewnętrznych im. Prof. A. Szczeklika, Oddział Kliniczny Pulmonologii i Alergologii Szpitala Uniwersyteckiego w Krakowie, Wydział Lekarski, Uniwersytet Jagielloński Collegium Medicum, Kraków, Polska
Klinika Chorób Wewnętrznych, Astmy i Alergii, Uniwersytet Medyczny, Łódź, Polska
Klinika Pneumonologii i Alergologii Wieku Dziecięcego, Warszawski Uniwersytet Medyczny, Warszawa, Polska
II Klinika Chorób Płuc, Instytut Gruźlicy i Chorób Płuc, Warszawa, Polska
Alergologia Polska – Polish Journal of Allergology 2021; 8, 3: 101–129
Piotrowski W, Barczyk A, Chciałowski A, et al. Statement of Polish Respiratory Society and Polish Society
of Allergology on the treatment of pulmonary complications
in patients after SARS-CoV-2 infection. Alergologia Polska - Polish Journal of Allergology. 2021;8(3):101-129. doi:10.5114/pja.2021.109379.
APA
Piotrowski, W., Barczyk, A., Chciałowski, A., Chorostowska-Wynimko, J., Czajkowska-Malinowska, M., & Kania, A. et al. (2021). Statement of Polish Respiratory Society and Polish Society
of Allergology on the treatment of pulmonary complications
in patients after SARS-CoV-2 infection. Alergologia Polska - Polish Journal of Allergology, 8(3), 101-129. https://doi.org/10.5114/pja.2021.109379
Chicago
Piotrowski, Wojciech J., Adam Barczyk, Andrzej Chciałowski, Joanna Chorostowska-Wynimko, Małgorzata Czajkowska-Malinowska, Aleksander Kania, and Maciej Kupczyk et al. 2021. "Statement of Polish Respiratory Society and Polish Society
of Allergology on the treatment of pulmonary complications
in patients after SARS-CoV-2 infection". Alergologia Polska - Polish Journal of Allergology 8 (3): 101-129. doi:10.5114/pja.2021.109379.
Harvard
Piotrowski, W., Barczyk, A., Chciałowski, A., Chorostowska-Wynimko, J., Czajkowska-Malinowska, M., Kania, A., Kupczyk, M., Sładek, K., Kulus, M., and Śliwiński, P. (2021). Statement of Polish Respiratory Society and Polish Society
of Allergology on the treatment of pulmonary complications
in patients after SARS-CoV-2 infection. Alergologia Polska - Polish Journal of Allergology, 8(3), pp.101-129. https://doi.org/10.5114/pja.2021.109379
MLA
Piotrowski, Wojciech J. et al. "Statement of Polish Respiratory Society and Polish Society
of Allergology on the treatment of pulmonary complications
in patients after SARS-CoV-2 infection." Alergologia Polska - Polish Journal of Allergology, vol. 8, no. 3, 2021, pp. 101-129. doi:10.5114/pja.2021.109379.
Vancouver
Piotrowski W, Barczyk A, Chciałowski A, Chorostowska-Wynimko J, Czajkowska-Malinowska M, Kania A et al. Statement of Polish Respiratory Society and Polish Society
of Allergology on the treatment of pulmonary complications
in patients after SARS-CoV-2 infection. Alergologia Polska - Polish Journal of Allergology. 2021;8(3):101-129. doi:10.5114/pja.2021.109379.
The aim of this document is to provide physicians treating patients with a history of COVID-19 pneumonia with recommendations on proper diagnostics and management of respiratory sequelae associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The expert panel provides 32 recommendations with respect to the treatment of lung consequences (including antibiotic therapy, corticosteroid therapy, and antithrombotic prophylaxis and treatment), pulmonary rehabilitation, lung transplantation, patient monitoring, and ambulatory settings. The management of patients with respiratory comorbidities (asthma, chronic obstructive pulmonary disease, lung cancer, and interstitial lung disease) and the medications used for treatment of these conditions, such as corticosteroids and antifibrotic drugs, is discussed. Presented recommendations are based on the most recent reports and aimed at providing patients post-COVID-19 respiratory sequelae with optimal standards of care.
